SPONSORSHIP PACKAGES AVAILABLE
Mike Peck — CRO, Endpoints News — email@example.com
This event has passed. Tickets are no longer available.
An industry veteran with more than 25 years working in clinical trial design and execution, Badhri Srinivasan is Head, Global Development Operations, Novartis. He leads a team of 4500 associates across 60 countries who conduct over 500 clinical trials for Novartis. He is a member of the Development Committee of Novartis (DCN).
Before joining Novartis, Badhri was CEO and co-founder of Remarque Systems, a technology company that develops state-of-the art disruptive technology solutions for the life sciences industry. Previously, he held several senior roles at Quintiles, most recently as senior vice president and head of global delivery network and global data and safety monitoring, leading a team of more than 5,000 across the Asia-Pacific, South Africa, Europe and North America.
A member of multiple scientific, academic and executive advisory committees, Srinivasan has represented numerous pharma companies at the FDA, EMA and MHRA. Also a member of the board of TransCelerate, and ACRES (Alliance for Clinical Research Excellence and Safety), he has been named to PharmaVOICE 100, the magazine’s list of the 100 most inspiring people in the life sciences industry.
In addition to clinical trial operations and process re-engineering, his work has involved development of mathematical algorithms to reduce cost and speed assets through clinic as well as new models of clinical development. He has patents pending on several of his algorithms. He holds an ABD in biostatistics from the University of North Carolina, Chapel Hill, and an MS in mathematical statistics from Bangalore University, India.
Tony Wood, SVP, Medicinal Science & Technology, joined GSK in October 2017. He is a member of the R&D Leadership Team, reporting to Hal Barron, President, R&D.
Tony was previously head of Worldwide Research & Development’s Medicinal Sciences at Pfizer, and prior to that held roles of increasing seniority in chemistry and medicinal sciences across a range of therapy areas. Tony played a leading role in the discovery of Maraviroc, a CCR5 antagonist for the treatment of HIV, and in recognition was awarded the RSC Malcolm Campbell Prize in 2005. He was also co-recipient of the ACS Heroes of Chemistry Prize, the Prix Galien USA and Scrip Awards in 2008, and the PhRMA Discoverers Award in 2010. In 2018 he was elected as a Fellow of the Academy of Medical sciences.
Tony is a named author and inventor on more than 50 publications and patents, and has represented the pharma view on UK funding council review boards, such as EPSRC and BBSRC.
Tony received his BSc and PhD in chemistry from the University of Newcastle upon Tyne, before
completing post-doctoral studies with Professor Steven Ley, FRS at Imperial College in London. He continues to be a Visiting Professor at the University of Newcastle upon Tyne.
Rosana Kapeller is an Entrepreneur in Residence at GV, focused on the intersection of therapeutics and machine learning. She brings over 25 years of scientific leadership and entrepreneurial experience to her role.
Rosana was the founding Chief Scientific Officer of Nimbus Therapeutics, where she led the company’s initiative to apply advanced computational technologies to the design and development of novel therapeutics. Rosana’s vision and leadership was instrumental in the discovery of the ACC inhibitor for NASH, acquired by Gilead. Previously, Rosana served as co-founder and VP of Research at Aileron Therapeutics. Early in her career, she spent 10 years at Millennium Pharmaceuticals, and also spent time as a consultant for Third Rock Ventures and Atlas Venture.
Rosana earned her M.D. from Universidade do Estado do Rio de Janeiro in Brazil and her Ph.D. in Molecular and Cellular Biology from Tufts University.
As Scientific Director, Discovery Data Sciences, Janssen Research & Development*, Hugo Ceulemans currently leads a multidisciplinary team that supports the different stages of drug discovery with machine learning approaches. The team unlocks data from a broad spectrum of sometimes unexpected data sources at industrial scale to advise project teams on selecting small molecules that may have the most promise of becoming a novel therapeutic.
Hugo holds the degrees of MD, MSc in Bioinformatics and Ph.D. in Molecular Biology. Prior to joining Janssen in 2008, he completed postdoctoral fellowships in molecular and computational biology at the University of Leuven, and in structural bioinformatics at the European Molecular Biology Laboratories in Heidelberg.
* Janssen Research & Development, LLC is part of the Janssen Pharmaceutical Companies of Johnson & Johnson
Dr. Saha is a physician-scientist, pharmaceutical executive, and biotech entrepreneur dedicated to discovering and developing novel cancer medicines.
He is notable for leading the development and demonstrating human effectiveness of two first-in-class cancer drugs, an ERK kinase inhibitor (Ulixertinib; BVD-523) and a bacteriolytic immunotherapy (C. novyi-NT).
Dr. Saha is the Senior Vice President of R&D and Global Head of Translational Medicine for all disease areas at Bristol-Myers Squibb. He is also the Site Head for Bristol-Myers Squibb R&D headquarters in Cambridge MA. Dr. Saha was a Venture Partner at Atlas, a venture capital firm in Cambridge MA, and most recently served as President and Chief Executive Officer at Delinia. In 2017, he led the acquisition of Delinia by Celgene for $775 million.
Previously he was Chief Medical Officer of Synlogic and a member on the Board of Directors of BioMed Valley Discoveries, a biotech company he played a pivotal role to launch as Chief Scientific Officer and subsequently serve as President for over 6 years. In 2005, Dr. Saha was recruited from McKinsey & Company to become the global head of the New Indications Discovery Unit at Novartis Pharmaceuticals. His work on developing new medicines has been featured in TIME Magazine, the Times, FOX, The Wall Street Journal and The Economist. Dr. Saha has published over 90 papers and patents (issued and pending) and his articles in the Nature and Science journals have been cited over 4000 times. He has been selected as a Harvard Medical School Global Clinical Scholar and a finalist for the White House Fellowship.
Shoibal Datta, PhD., is vice president and head of product and technology at PPD. He is responsible for the virtual trial technology platform and developing a technology roadmap that creates bests-in-class differentiation. Dr. Datta determines the optimal way to construct a platform through partnerships, investments and internal development initiatives and is ultimately responsible for the successful patient, investigator and customer user interface and experience.
Dr. Datta joined PPD from a large biotechnology company where he held diverse roles over 13 years, most recently as head of informatics and technology within a value-based medicine group. For three prior years, Dr. Datta directed the life sciences practice at a scientific consulting company in the biotechnology and pharmaceutical industries. These roles gave him broad-based experience in biotechnology, healthcare and pharmaceutical strategy and processes, key business drivers, and various enabling technologies, specifically eHealth, mHealth and translational informatics. Dr. Datta has a proven track record in the strategic development and effective management of complex scientific and business programs at the executive and senior executive levels.
Dr. Datta holds a Bachelor of Science in life sciences and biochemistry from St. Xavier’s College in Bombay, India, and a doctorate in molecular biology and biochemistry from the University of California at Irvine.
John D. Carroll is a biotech analyst and writer with decades of prize-winning experience in journalism.
A co-founder of Endpoints News, he has covered biopharma for the past 15 years. Aside from his previous daily industry coverage at FierceBiotech, where he was named editor in 2003, leaving in 2016, Carroll has been a regular speaker at biotech events around the globe. He’s been quoted by The New York Times, The New Yorker, Financial Times, The Times of London and more. He’s also keynoted at biotech gatherings around the world and addressed student audiences at MIT and Harvard.
Carroll has contributed stories from Central America and Ireland to the Dallas Morning News and Time and wrote for the Houston Press. He spent 6 years as editor and publisher of the Dallas Business Journal, was publisher of Texas Businessand early in his career was part of a Pulitzer Prize-winning team of reporters and editors at the Kansas City Star & Times.